Literature DB >> 18695635

Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients.

Masatomo Miura1, Hideaki Kagaya, Shigeru Satoh, Kazuyuki Inoue, Mitsuru Saito, Tomonori Habuchi, Toshio Suzuki.   

Abstract

Mycophenolic acid (MPA) is mainly glucuronized by uridine diphosphate-glucuronosyltransferases (UGTs) into the phenolic MPA glucuronide (MPAG). MPAG is excreted by transporters such as organic anion-transporting polypeptide (gene SLCO), multidrug resistance protein 2 (gene ABCC2), breast cancer resistance protein (BCRP, gene ABCG2) or P-glycoprotein (gene ABCB1). This study investigated the association of UGTs, SLCOs, ABCB1, ABCC2, and ABCG2 polymorphisms with MPAG pharmacokinetics in 80 Japanese renal transplant recipients. Eighty recipients were given repeated doses of combination immunosuppressive therapy consisting of mycophenolate mofetil and tacrolimus every 12 hours at a designated time (0900 and 2100). On day 28, after renal transplantation, plasma concentrations of MPA and MPAG were measured by high-performance liquid chromatography. There were no significant differences in the area under the plasma concentration-time curve (AUC) ratio of MPAG/MPA between UGT1A1, UGT1A6, UGT1A7, UGT1A8, and UGT1A9 I399C/T genotypes. On the other hand, the median dose-adjusted AUC0-12 of MPAG in SLCO1B1 1a/1a+1a/1b+1b+1b (n = 53) and 1a/*15 + 1b/*15+*15/*15 (n = 27) were 1549 and 1134 mg.h L g, respectively (P = 0.03004 in multivariate analysis). The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis). There were no significant differences in the dose-adjusted AUC0-12 of MPAG between the ABCB1 C3435T and ABCC2 C-24T genotypes. However, the dose-adjusted AUC0-12 of MPAG was significantly lower in recipients with ABCG2 421C/A+A/A (n = 44) than in those with C/C (n = 36) (P = 0.0295). In conclusion, our findings showed that MPAG pharmacokinetics were significantly influenced by SLCO1B1 and SLCO1B3 polymorphisms and not by UGT polymorphisms. BCRP rather than multidrug resistance protein 2 seems to be the transporter associated with biliary excretion of MPAG.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18695635     DOI: 10.1097/FTD.0b013e3181838063

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  23 in total

1.  Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity.

Authors:  Ute I Schwarz; Henriette E Meyer zu Schwabedissen; Rommel G Tirona; Atsuko Suzuki; Brenda F Leake; Younes Mokrab; Kenji Mizuguchi; Richard H Ho; Richard B Kim
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

2.  Steady-state pharmacokinetics of mycophenolic acid in renal transplant patients: exploratory analysis of the effects of cyclosporine, recipients' and donors' ABCC2 gene variants, and their interactions.

Authors:  N Božina; Z Lalić; S Nađ-Škegro; A Borić-Bilušić; T Božina; Ž Kaštelan; V Trkulja
Journal:  Eur J Clin Pharmacol       Date:  2017-06-18       Impact factor: 2.953

3.  Human ABCG2: structure, function, and its role in multidrug resistance.

Authors:  Wei Mo; Jian-Ting Zhang
Journal:  Int J Biochem Mol Biol       Date:  2011-03-30

4.  Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Authors:  Adam Frymoyer; Davide Verotta; Pamala Jacobson; Janel Long-Boyle
Journal:  Br J Clin Pharmacol       Date:  2013-02       Impact factor: 4.335

5.  CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients.

Authors:  Nicolas Picard; Koukeb Rouguieg-Malki; Nassim Kamar; Lionel Rostaing; Pierre Marquet
Journal:  Transplantation       Date:  2011-03-27       Impact factor: 4.939

Review 6.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2013-05       Impact factor: 6.447

8.  The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

Authors:  N Picard; S W Yee; J-B Woillard; Y Lebranchu; Y Le Meur; K M Giacomini; P Marquet
Journal:  Clin Pharmacol Ther       Date:  2009-11-04       Impact factor: 6.875

9.  No impact of age on dose-adjusted pharmacokinetics of tacrolimus, mycophenolic acid and prednisolone 1 month after renal transplantation.

Authors:  Masatomo Miura; Shigeru Satoh; Hideaki Kagaya; Mitsuru Saito; Takamitsu Inoue; Norihiko Tsuchiya; Toshio Suzuki; Tomonori Habuchi
Journal:  Eur J Clin Pharmacol       Date:  2009-10       Impact factor: 2.953

10.  Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients.

Authors:  Nayoung Han; Hwi-yeol Yun; In-Wha Kim; Yoon Jung Oh; Yon Su Kim; Jung Mi Oh
Journal:  Eur J Clin Pharmacol       Date:  2014-08-28       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.